Transforming Epilepsy Care

Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford  Epilepsy Center. He had research awards from the Klingenstein  Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles  and 4 books. He was named 1996-2016 in Best Doctors in America.  Dr. Fisher is Past-President of the American Epilepsy  Society, and has 

Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford  Epilepsy Center. He had research awards from the Klingenstein  Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles  and 4 books. He was named 1996-2016 in Best Doctors in America.  Dr. Fisher is Past-President of the American Epilepsy  Society, and has served on the Board of the ILAE and as Editor-in-Chief  of the Journal, Epilepsia.  His research is on new devices to treat epilepsy.   

Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology,  up until October 2016, when purchased by Google. He  continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual real

Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology,  up until October 2016, when purchased by Google. He  continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual reality (VR) headsets.  He now serves as the President of Parallel Rules consulting firm.  

Steve brings 30+ years of leadership and strategy experience in the Medical Device industry.  He has held a variety of leadership roles in various cross functional areas.  Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis.  Under his leadership, the company

Steve brings 30+ years of leadership and strategy experience in the Medical Device industry.  He has held a variety of leadership roles in various cross functional areas.  Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis.  Under his leadership, the company has grown in revenues, remained debt-free, and has expanded into new markets. 

Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives.  He currently services as a Partner for 

Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives.  He currently services as a Partner for Ventac Partners and a Senior Advisor for Mesa Partners.  He is also a parent of a child with epilepsy.

Erik Janssen is the Head of Digital Transformation Immunology and Neurology at UCB Pharma, the global leaders in the field of epilepsy research and medicine development. Erik brings 25+ years of global executive experience in pharma and digital health innovation. In his current role, Erik leads an international mission whose focus is on i

Erik Janssen is the Head of Digital Transformation Immunology and Neurology at UCB Pharma, the global leaders in the field of epilepsy research and medicine development. Erik brings 25+ years of global executive experience in pharma and digital health innovation. In his current role, Erik leads an international mission whose focus is on investigating technology solutions with potential to make a meaningful difference to the lives of people living with neurological conditions like epilepsy and Parkinson’s Disease.